Arvinas (NASDAQ:ARVN) Price Target Lowered to $51.00 at Stifel Nicolaus

Arvinas (NASDAQ:ARVN) had its price objective decreased by Stifel Nicolaus from $63.00 to $51.00 in a research note released on Wednesday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Other analysts have also issued reports about the stock. Stephens began coverage on shares of Arvinas in a report on Monday, November 18th. They set an “overweight” rating and a $55.00 target price for the company. Oppenheimer lowered their price target on Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. Wedbush restated an “outperform” rating and set a $57.00 target price on shares of Arvinas in a report on Tuesday. Finally, Barclays cut their price target on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $59.58.

Arvinas Stock Performance

Shares of ARVN stock opened at $17.95 on Wednesday. The company has a market capitalization of $1.23 billion, a P/E ratio of -3.84 and a beta of 1.88. Arvinas has a fifty-two week low of $16.61 and a fifty-two week high of $53.08. The stock has a 50 day moving average price of $19.18 and a two-hundred day moving average price of $23.32.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. During the same quarter in the prior year, the business earned ($2.53) EPS. As a group, equities analysts predict that Arvinas will post -3.22 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in Arvinas by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company’s stock valued at $135,389,000 after buying an additional 56,561 shares in the last quarter. FMR LLC grew its stake in shares of Arvinas by 7.6% in the third quarter. FMR LLC now owns 2,883,604 shares of the company’s stock worth $71,023,000 after acquiring an additional 204,317 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Arvinas by 18.7% in the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after acquiring an additional 367,343 shares during the last quarter. Braidwell LP increased its holdings in shares of Arvinas by 148.3% during the third quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock valued at $31,637,000 after acquiring an additional 767,242 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC raised its position in shares of Arvinas by 1.4% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,244,450 shares of the company’s stock worth $30,651,000 after purchasing an additional 17,723 shares during the last quarter. 95.19% of the stock is currently owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.